India's Ranbaxy gets US FDA approval for cardiac treatment drug Pravastatin |
|
|
|
Published
:
Wed, 25 Apr 2007 12:33
|
MUMBAI (Thomson Financial) - India's Ranbaxy Laboratories Ltd said it has received approval from the US Food and Drug Administration to manufacture and market cardiac treatment drug Pravastatin.Pravastatin is the generic version of Bristol Myers Squibb's Pravachol and is indicated in the treatment of primary prevention of coronary events such as in hypercholesterolemic patients without clinically evident coronary heart disease.Total annual market sales for all strengths of the drug were 1.19 bln usd in 2006.sourav.mishra@thomson.comsmi/ra/gpCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Ranbaxy gets approval to market generic Cefprozil in Canada 